Navigation Links
Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
Date:10/9/2008

SKOKIE, Ill., Oct. 9 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, announced today that Robert J. De Vaere has joined the Company as executive vice president and chief financial officer.

"Bob is an experienced executive who brings more than 28 years of financial management experience to Horizon, including the last decade in healthcare with both public and private companies," said Timothy P. Walbert, president and chief executive officer. "During his career, Bob has been instrumental in numerous M&A transactions as well as an IPO and will be an important part of Horizon's future growth."

Mr. De Vaere's most recent position was as senior vice president, finance and administration and chief financial officer of IDM Pharma, Inc. (Nasdaq: IDMI), a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer. Additionally, Mr. De Vaere served as vice president, finance and administration and chief financial officer of IDM Pharma from August 2005 to March 2006, and was vice president and chief financial officer of Epimmune from May 2000 until the business combination with IDM Pharma in August 2005.

Mr. De Vaere has also served as chief financial officer of Nexa Orthopedics, which was acquired by Tornier, Inc. and vice president of finance and administration and chief financial office of Vista Medical Technologies, Inc., a medical device company.

Earlier in his career, Mr. De Vaere held accounting, finance and administrative positions within the electronics and aerospace industries. Mr. De Vaere received a bachelor's degree from the University of California, Los Angeles.

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit http://www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Out beyond the horizon
2. Out beyond the horizon
3. BioHorizons Announces Agreement to Purchase Implant Logic Systems
4. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
5. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
6. BioHorizons Announces the Purchase of Implant Logic Systems
7. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
8. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
9. Horizon Therapeutics to Present at UBS Global Life Sciences Conference
10. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics today ... move comes after the company changed focus to making analytical tools for biopharmaceutical ... our new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and ...
(Date:4/19/2017)... ... April 19, 2017 , ... As ... educational webinars accessible to novices as well as experienced users, attendees will gain ... performed coagulation screening tests. , Hemostasis testing quality is determined by preanalytical ...
(Date:4/19/2017)... , April 19, 2017 ... today announced that it will report its first ... on Wednesday, May 3, 2017. Following the announcement, Veracyte,s management will ... p.m. Eastern Time to discuss the company,s financial results ... and subsequent replay may be accessed by visiting Veracyte,s website ...
(Date:4/18/2017)... ... April 18, 2017 , ... For a historic seventh ... in the VaxCorps vaccine consortium, were named one of the top two Clinical Research ... inception of this category; winning the award four times previously, and first runner up ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):